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Abstract
Triple-negative breast carcinomas constitute a wide spectrum of lesions, mostly being highly aggressive. Nevertheless, some
special histologic subtypes can have lowmalignant potential. The purpose of the present paper is to review diagnostic criteria and
prognostic parameters of breast neoplasms of special histotypes. Specifically, adenoid cystic carcinoma, adenomyoepithelioma,
acinic cell carcinoma, mucoepidermoid carcinoma, tall cell carcinoma with reverse polarity, and secretory carcinoma will be
discussed. For each tumour, definition and morphological and molecular features, together with prognostic parameters, will be
presented. Paradigmatic cases will be illustrated.
Keywords Triple-negative breast carcinoma . Adenoid cystic carcinoma . Adenomyoepithelioma . Acinic cell carcinoma .
Mucoepidermoid carcinoma . Tall cell carcinomawith reverse polarity . Secretory carcinoma
Introduction
Triple-negative breast carcinomas (TNBCs) are invasive
breast carcinomas lacking oestrogen receptor (ER) or proges-
terone receptor (PR) expression and HER2 amplification. The
term TNBC has acquired an ominous meaning as in most of
the cases it refers to poorly differentiated breast carcinomas,
with highly aggressive behaviour. Normal breast glands are
composed of different cells, not all expressing hormone recep-
tors but all of them having the ability to transform into malig-
nant tumours of varying clinical behaviour. Therefore, even if
rarely, TNBC of low malignant potential can occur [1].
Despite the attention toward these histologic subtypes has
grown in the last decade, knowledge on TNBC of low malig-
nant potential is still limited due to their rarity. Lack of knowl-
edge can result in inappropriate treatment.
The purpose of the present paper is to review the recent
literature on TNBC of low malignant potential, focusing on
diagnostic criteria and prognostic features. The main features
of each tumour are summarized in Table 1.
Tumours with epithelial and myoepithelial
differentiation
Adenoid cystic carcinoma (AdCC)
AdCC is an invasive carcinoma composed of epithelial and
myoepithelial cells, arranged in tubular, cribriform and solid
structures [2]. It is morphologically similar to the salivary
gland counterpart, but of low malignant potential when affect-
ing the breast.
AdCC affects mainly adult and elderly women, but on rare
occasions can affect young and male patients (review in ref.
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[3]). It presents more frequently as a single, palpable nodule
located in the retroareolar region.
The increased use of screening mammography has led to
the detection of small forms arising in all breast quadrants. On
very rare occasions AdCC can be multifocal [4].
AdCC presents as a mass with regular margins, which can
be misdiagnosed as fibroadenoma on imaging [5].
Pre-operative diagnosis can be challenging, if the possibil-
ity of a salivary gland-like carcinoma is not kept in mind.
Fine-needle aspiration cytology can be difficult to interpretate,
characterized by basaloid cells surrounding hyaline globules
with a microcystic pattern. The differential diagnosis between
AdCC and collagenous spherulosis can be very difficult and
requires histology [6, 7]. Pre-operative diagnosis based on
core needle biopsy (CNB) can be made based on the same
criteria applied on surgical specimens with the aid of
immunohistochemistry.
On histology, breast AdCC can exhibit three different sub-
types, with prognostic impact [2].
AdCC classic variant (C-AdCC) (Fig. 1). Most frequently shows
cribriform architecture with glandular spaces surrounded by ep-
ithelial cells and pseudo-glandular spaces lined by myoepithelial
cells. Peripheral areas with tubular architecture can be seen.
Necrosis is absent and mitotic figures are rare. Perineural inva-
sion is rare. On immunohistochemistry, markers of basement
membrane such as collagen IV and laminin highlight the content
of the pseudovascular spaces. Epithelial and myoepithelial
markers are useful to show the biphasic nature of the tumour.
CD117 is usually diffusely positive especially staining the epi-
thelial cells. Strong and diffuseMYB expression by immunohis-
tochemistry can be used to support a diagnosis of AdCC, report-
ed in 65–100% of the cases [8–10].
AdCC solid-basaloid variant (SB-AdCC) (Fig. 2). In addition to
the classic AdCC features, it is composed of solid areas, with
nuclear atypia and high mitotic count [11]. Necrosis and peri-
neural invasion are frequently detected [12].
AdCC with high-grade transformation (HG-AdCC) Very rare
cases of AdCC associated with different types of cancer have
been reported [13]. The carcinomas associated with AdCC are
frequently aggressive types, such as small cell carcinoma [14],
invasive carcinoma of no special type [15]. In addition, rare
cases of AdCC associated with adenomyoepithelioma (AME)
have been reported [16].
In situ AdCC Intraductal component of AdCC has been origi-
nally reported and illustrated by Rosen [17] as a polypoid
intraductal growth.
Molecular data Breast AdCC is usually devoid of ER/PR ex-
pression or HER2 amplification. In a minority of cases, rare
epithelial cells can express ER [18]. Vranic et al. demonstrated
that AdCC can express a rare ER isoform, namely ER-α36
[19]. Recently, Yiğit et al. [20] reported androgen receptor
positivity in 7 cases of breast AdCC. The therapeutic value
of these findings has yet to be investigated.
On molecular analyses breast AdCC frequently harbours
MYB-NFIB fusion gene orMYBL1 rearrangements orMYB am-
plification. These alterations can activate downstream signals that
are potentially therapeutic targets [21]
Recently an unusual case of AdCC with adipocytic differ-
entiation carrying BRAF mutation has been reported [22].
Most of the published data are based on C-AdCC. More
recently, Massè et al. [23] compared 16 cases of C-AdCCwith
17 cases of SB-AdCC by RNA-seq expression analysis, dem-
onstrating 549 genes having a differential expression profile.
Most importantly,NOTCH andCREBBPmutations were only
detected in SB-AdCC. Notch signalling pathway can be a
potential therapeutic target.
C-AdCC should be differentiated from several lesions. C-
AdCC with prominent cribriform architecture can be easily
differentiated from cribriform carcinoma of the breast as the
latter is strongly and diffusely ER positive and lacks positivity
for myoepithelial markers. The distinction between AdCC and
collagenous spherulosis (CS) of the breast can be more chal-
lenging. CS is a benign condition, characterized by spherules
of basement membrane in association with florid epiheliosis/
usual ductal hyperplasia. Diffuse and strong positivity for sev-
eral myoepithelial markers, together with absence of CD117
and MYB positivity favour the diagnosis of CS [24, 25].
C-AdCC with tubular growth pattern should be differenti-
ated from microglandular adenosis (MGA) [26]. AdCC tubu-
lar variant is composed of epithelial and myoepithelial cells,
both being evident by the application of appropriate immuno-
histochemical markers, at variance with MGA that is com-
posed of epithelial cells only.
SB-AdCC can simulate neuroendocrine carcinoma. The dif-
ferential diagnosis can be easily made based on immunohisto-
chemistry as neuroendocrine markers are completely negative in
SB-AdCC. Differentiation from conventional TNBC could be
more difficult, and the diagnosis of SB-AdCC should be based
on the presence of at least focal features of C-AdCC, strong and
diffuse expression of MYB by immunohistochemistry or MYB-
NFIB rearrangement by FISH [27].
The prognosis of AdCC mostly depends on the stage at pre-
sentation and AdCC variants. C-AdCC usually carries a good
prognosis, despite the triple-negative phenotype. Almost all stud-
ies but one [28] demonstrated that C-AdCC recurrences or pro-
gression to metastases are exceedingly rare. Nevertheless, care
should be taken to radically excise AdCC.We observed a case of
C-AdCC recurring as HG-AdCC after 11 years. An 84-year-old
woman presented in 2008 with a 5.5-cm tumour mass affecting
the left breast. After the diagnosis of C-AdCC, the patients
underwent surgery. The tumour was excised, but the margins
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were not clear. Due to the advanced age of the patient and low
malignant potential tumour, a wait and see approach was ad-
vised. In 2019, 11 years later, the patient presented with a huge
tumour mass, involving the whole residual breast. On histology
the AdCC showed features of SB-AdCC and of HG-AdCC, in
addition to features of C-AdCC (Fig. 1, Supplementary
materials).
Therefore, radical surgery is considered the treatment of
choice. Recurrences and metastases can occur in SB-AdCC
[2, 3, 12].
The prognosis of AdCC with associated other types of
carcinoma depends mainly on the associated malignancy.
Adenomyoepithelioma and its malignant counterpart
Adenomyoepithelioma (AME), first described by Hamperl in
1970 [29], is a rare biphasic neoplasm characterized by the
proliferation of ductal epithelial cells and myoepithelial cells
[2]. Since the original description, numerous papers on AME
have been reported [30]. Nevertheless, due to its rarity, most
papers were single case reports or small series. Only rare stud-
ies were based on series larger than 15 cases (Table 1 in
supplementary files).
AME predominantly affects elderly women over 60 years
and is rarely seen in males [31]. It usually presents as a solitary
palpable mass or as screen detected small nodule. It can arise
in the retroareolar region [2]. Rare cases of multicentric AME
have been reported [32]. Mammography reveals round or oval
mass with lobulated margins, sometimes associated with
rough heterogeneous calcifications [33]. Ultrasound identifies
hypoechogenic lesions. MRI exhibits isointensity on T1W1
and high signal intensity on T2W1 [34].
AME diagnosis can be very difficult on fine-needle aspira-
tion cytology and sometimes it can simulate fibroadenoma. A
more accurate diagnosis can be rendered on core needle biop-
sies [35].
Fig. 1 C-AdCC; a the central
component of the tumor shows
the typical cribrifom architecture,
while in the peripheral part the
tubular achitecture predominates.
b AdCC with tubular architecture
is composed of glands lined by
epithelial and myoepithelial cells.
The glands contain mucous or
basal membrane. c C- AdCCwith
cribriform architecture is
composed of neoplastic nests
showing glandular structures
containing mucous and of
pseudoglandular spaced
containing basal membrane
invaginations (arrows); d The
epithelial cells are CD117
positive; e p63 highlights the
presence of myoepithelial cells in
the tubular areas
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Macroscopically, AMEs are solid, well-circumscribed, of-
ten multi-lobulated lesions. Some AMEs have a papilloma-
tous component with focal cystic change and calcification. On
the other hand, malignant AMEs (AME-M) are not well-
circumscribed and larger tumours [36].
On histology, AME exhibits a variable morphological
spectrum. Diagnosis is based on the classical proliferation of
both epithelial and myoepithelial cells.
The correlation between histological variants and progno-
sis is controversial.
Aspects of difficult interpretation may be encountered,
which are summarized as follows:
Classical AME (C-AME) is the best known and illustrated
form. It is characterized by glands lined by a double cell
layers, the inner epithelial layer and the outer myoepithelial
layer (Fig. 3). Based on architectural and cytological features,
AME can be subdivided into: spindle cell, tubular, lobulated,
papillary, and mixed [2, 30, 36–38]. Myoepithelial cells can
have spindle shape or epithelioid appearance with clear cyto-
plasm. Apocrine, squamous, or sebaceous metaplasia can oc-
cur in luminal epithelial cells [36]. The tubular AME is char-
acterized by small glandular structures which can grow by
infiltrating the surrounding tissue. The tubular pattern has
been illustrated in early papers [39, 40] and named as apocrine
adenosis [40].
AME can exhibit a prominent intraductal, papillary, growth
(IP-AME) [38]. IP-AME can grow along the ductal system of a
breast lobe, resulting in a multinodular proliferation.
Atypical AME (A-AME) (Fig. 4): Cytological atypia can be
encountered in both epithelial and myoepithelial components.
Criteria to define cytological atypia in breast AME have not been
standardized. Applying the same criteria used in salivary glands
[41], atypia should be considered when neoplastic cells (both
epithelial or myoepithelial) are 3 times larger than normal cells
Fig. 2 SB-AdCC; a at low power view it is composed of multiple solid
neoplastic nests; b at higher power the neoplastic nests are composed of
markedly atipical cells, necrosis is often present; c SBAdCC is composed
of cells with markedly atipica nucleus and scanty cytoplasm that must be
differentiated from neuroendocrine carcinoma; d Neoplastic cells are
diffusely CD117 positive; e Nuclear positivity for MYC
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(internal reference used: epithelial cells of normal mammary
glands), have larger nucleus with coarse chromatin and irregular
nuclear contour, nucleolus can be prominent. Cytological atypia
is more frequently observed in the myoepithelial cells. A-AME
can show features of myoepithelial overgrowth, when the
myoepithelial cell proliferation is so prominent that it blurs the
epithelial component.
Mitotically active AME (MA-AME) (Fig. 5). The number of
mitotic figures is highly variable, ranging from none to more
than 10 in 10 high-power fields (HPF) (summary in table 2
supplementary files). The definition of MA-AME should be
applied in those C-AME, devoid of any atypia, with a high
number of mitotic figures. The prognostic impact of the
Fig. 3 C-AME; a C-AME with lobulated architecture; b C-AME with
intraductal papillary component; cAt high power C-AME is composed of
glandular strucutres lined by a inner layer of eosinophilic epithelial cells
and by an outer layer of clear, myoepithelial cells; d C-AMEwith tubular
architecture: at a variance ofMGA, glands are lined by a double cell layer
Fig. 4 A-AME is composed of large cells, with atipical nucleous with
coarse chromatin and evident nucleoli. Mitotic figures are frequent
Fig. 5 MA-AME has the same cell composition of C-AME, but presents
frequent mitotic figures
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mitotic count in C-AME is not clear. The AFIP book [42]
suggests that cases with more than 3 mitotic figures in 10
HPF are at higher risk of recurrence. Nevertheless, no clinical
validation has been obtained on this number. Reviewing the re-
ported cases (table 2 supplementary files), a highmitotic count has
been reported mainly in AME with malignant transformation;
therefore, the impact of mitotic count in otherwise C-AME is still
unknown.
Malignant in situ AME (MIS-AME): According to Rakha
et al. [30], MIS-AME should be diagnosed when the epithelial
component of C-AME shows features of ductal carcinoma in
situ. InMIS-AME, the malignant epithelial cells do not invade
the stroma outside the AME mass (Fig. 6).
Conventional ductal or lobular carcinoma in situ can be asso-
ciated with AME, but outside the AME neoplastic mass [43–45].
These latter cases should not be identified as MIS-AME.
Malignant AME (M-AME) (Fig. 7): M-AME is diagnosed
when either luminal epithelial and/or myoepithelial cell com-
ponent becomes malignant. M-AME may develop from a
long-s tand ing C-AME [39] or de novo (F ig . 2
Supplementary files). Cases showing malignant transforma-
tion of both epithelial and myoepithelial cells are named
epithelial-myoepithelial carcinoma [2].
M-AME is diagnosed when it shows marked cytologic
atypia, numerous mitotic figures, necrosis, and infiltrative
growth pattern. On some occasions, M-AME can exhibit a
multinodular growth pattern.
When malignant transformation occurs in the epithelial
component, it can show a great variety of morphological pat-
terns. Specifically, the reported malignant components are
low-grade adenosquamous and sarcomatoid carcinomas
[46], multifocal adenosquamous carcinoma [47], matrix pro-
ducing metaplastic carcinoma, acantholitic variant of squa-
mous carcinoma, carcinosarcoma, spindle cell carcinomas
[48–54], and mucoid carcinoma [46].
Dual differentiation of the neoplasm can be demonstrated
by immunohistochemistry (IHC). Myoepithelial cells express
p63, smooth muscle actin (SMA), cytokeratin 5/6 and 14, and
CD10. Luminal epithelial cells express low molecular weight
cytokeratins (Cam5.2, CK7, and CK8/18). Paradoxical ex-
pression of high-molecular weight cytokeratins in the epithe-
lial component can be observed [55].
Oestrogen or progesterone receptor (ER, PR) can be positive
or negative; Her2-neu is negative. Genetic alterations of AMEs
differ according to their ER status. Oestrogen receptor-positive
AMEs havemutations in phosphoinositide 3-kinase (PI3K) path-
way genes, whereas ER-negative AMEs usually harbour concur-
rent mutations affecting the HRAS Q61 hotspot and PI3K path-
way genes [56–60]. However, a recent ER-positive AME has
been reported presenting both HRAS and PIK3CA mutations
[60]. EGFR gene amplification has been recently reported [58].
Malignant transformation can alter ER expression status in
AME as reported in one case showing ER-positive AME as-
sociated with ER-negative carcinoma [55].
Pleomorphic adenoma, adenoid cystic carcinoma, and low-
grade adenosquamous carcinomas are included in the differ-
ential diagnosis.
Pleomorphic adenoma of the breast similar to AME is a bi-
phasic tumour, characterized by glandular structures lined by a
double cell layers (epithelial and myoepithelial) in
chondromyxoid matrix [2]. At variance with C-AME,
myoepithelial cells in pleomorphic adenoma glands are flat and
not prominent. Both adenoid cystic carcinomas and low-grade
adenosquamous carcinomas have infiltrative growth pattern.
Adenoid cystic carcinomas usually have a cribriform pattern
and basaloid myoepithelial cells. Low-grade adenosquamous
carcinomas typically have abundant desmoplastic stroma and
less myoepithelial component [60]. Nevertheless, all these tu-
mours are part of the spectrum of breast tumours composed of
epithelial and myoepithelial cells; therefore, their features can
merge. Mixed tumours showing features of C-AME associated
with pleomorphic adenoma [31], C-AME and adenoid cystic
carcinoma [61], and C-AME and low-grade adenosquamous
carcinoma [46] have been reported.
C-AME with papillary growth must be differentiated from
benign intraductal papilloma. Intraductal papilloma can show
Fig. 6 MIS-AME; amalignant transformation of the epithelial componenti is seen; b Smoothmuscle actin evidences the myoepithelial cells compressed
by the epithelial proliferation
Virchows Arch
focal myoepithelial hyperplasia, therefore rendering this dif-
ferential diagnosis quite subjective and challenging. C-AME
with papillary growth should be diagnosed when
myoepithelial hyperplasia is prominent and diffuse in the
whole lesion. Recently, monoclonal antibodies recognizing
Q61R mutant NRAS and KRAS have been generated and
demonstrated to stain positive in most ER-negative C-AME
[57]. The application of these antibodies, where available, can
be of help in the diagnosis of ER-negative C-AME. If immu-
nohistochemistry is not available, diagnosis should be based
on the presence of prominent myoepithelial layer.
Pure metaplastic carcinoma is the major differential diag-
nosis in de novo M-AME as both can have biphasic compo-
nents. The association with C-AME or A-AME would be the
clue to diagnose M-AME. Another evidence to exclude meta-
plastic carcinoma is HRASQ61Rmutations which occur with
PIK3CA or PIK3R1 mutations, recently found to be highly
specific for ER-negative M-AME [56]
C-AMEs have a favourable clinical course. Nevertheless,
local recurrences can occur. Some AMEs with multinodular
growth pattern may have local recurrence. Existence of satel-
lite nodules and peripheral intraductal growth seem to be as-
sociated with recurrence [36]. Rare cases of C-AME devoid of
any atypical features at presentation developed distant
metastases [62, 63]. Thus, most AMEs are cured by complete
surgical resection with clear margins but follow-up should be
advised for all patients with AME.
Other parameter indicating tendency to recur is the infiltra-
tive growth pattern.
AMEs with large size, pure solid growth, myoepithelial
component overgrowth, invasive growth pattern, cytological
atypia, and abundant mitotic activity are suggestive of malig-
nant transformation [30, 36].
M-AME has local recurrence and metastatic potential. The
histologic subtype and the grade of the invasive carcinoma
determine the prognosis. Lung is the most common site of
metastasis followed by liver, bone and brain while lymph
node metastases are rare [30].
Tumours with pure epithelial differentiation
Mucoepidermoid carcinoma (MEC)
Breast MEC is a carcinoma composed of mucoid, epidermoid,
and intermediate cells [2]. It shares the same features of the
salivary gland counterpart.
Fig. 7 M-AME malignant transformation is evident in both, epithelial and myoepithelial component. a, b at low power view the myoepithelial cells
predominate; c Both epithelial and myoepithelial cells show marked nuclear atypia
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Clinical presentation is non-specific. MEC arises in adult
women; any breast quadrant can be affected. It presents as a
nodule, with well-defined margins and cystic component. The
imaging appearance can mimic a benign lesion [64].
Fine-needle aspiration cytology can be difficult to interpret.
In cases of high-grade MEC, the presence of atypical cells
with both glandular and epidermoid differentiation can lead
to the correct diagnosis of carcinoma [65, 66]. Ancillary stud-
ies can help to better specify the tumour histotype. The pre-
operative diagnosis can be made on core needle biopsy. The
most important clue is to keep in mind that salivary gland-like
tumours can occur in the breast.
On histology (Fig. 8), MEC is composed of mucous, inter-
mediate and epidermoid cells. True keratinization with squa-
mous pearls should be excluded.
Breast MEC morphology varies according to the grade.
Grade should be performed either according to the breast
criteria or applying salivary gland criteria [67].
Low-grade MEC usually shows a prominent cystic compo-
nent and well-defined margins. The cysts are lined by mucous
and eosinophilic cells. Mucous cells can, sometimes, have a
signet ring appearance. The neoplastic cells are usually ar-
ranged in nests, with the mucous and eosinophilic cells locat-
ed in the centre and epidermoid cells located at the periphery.
The most peripheral cell layer is composed of basaloid cells.
High-grade MEC shows the same cell composition, but
with higher degree of solid architecture and cytologic atypia.
Necrosis can be present. Atypical mitotic figures are frequent.
Cases of intermediate grade can be encountered.
In situ component can be seen, characterized by an
intraductal papillary proliferation, showing the classical mu-
cous cells intermingled with the epidermoid cells.
Immunohistochemistry can help to demonstrate the
peculiar architecture and cell composition. High-
molecular weight cytokeratins (such as CK14 and
CK5/6) and p63 typically stain the epidermoid and the
basaloid cells located at the peripheral part of the neo-
plastic nests and cysts. Low molecular weight CK (such
as CK7) stains the centrally located mucous and the
eosinophilic cells [64, 67, 68].
Breast MEC can be positive for the anti-mitochondrial an-
tigen [67].
Breast MEC do not express hormone receptors nor have
HER2 amplification.
Salivary gland MEC typically shows CRTC1/MAML2
translocation. Rare cases of breast MEC were shown to have
MAML2 rearrangements [69–71].
Breast MEC should be differentiated from all other carci-
nomas with divergent, adenosquamous differentiation and
from metaplastic carcinomas with squamous differentiation.
Fig. 8 MEC: a Low power view of low-grade mucoepidermoid carcinoma with prominent cystic component; b and c at higher power the cysts are lined
by epithelium with mucoid and epidermoid cells
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Differential diagnosis can be difficult, especially for the high-
grade MEC.
The presence of true keratinization and squamous pearls
should discourage the diagnosis of MEC.
Detection of MAML2 rearrangements can be of help [70]
as they are absent in other breast carcinomas. Whenmolecular
tools are not available, detecting the typical alternation of
cytokeratins (high molecular weight in the peripheral part
and low molecular weight in the central part of the neoplastic
nests) can help.
Prognosis largely depends on MEC grade [72]. Ye et al.
[64] reviewed 41 cases of breast MEC reported in the litera-
ture. Axillary lymph node metastases can occur both in low-
and high-grade MEC, while distant metastases have been de-
scribed in high-grade cases only. None of the low-grade MEC
caused patient’s death, while death occurred in 4 of 11 high-
gradeMECs. One case of low-grade MEC recurred with high-
grade transformation [73]; nevertheless, the patient was alive
with no evidence of disease 156 months after presentation.
Acinic cell carcinoma (ACC)
Breast ACC is composed of cells showing features of serous
acinar differentiation, characterized by intracytoplasmic eo-
sinophilic zymogen granules [2].
Clinical presentation is non-specific. ACC affects mainly
adult women, with only 1 male patient reported in the litera-
ture [74]. ACC can arise in any breast quadrants, presenting as
an infiltrative nodule; size varies sometimes reaching large
dimensions [75, 76]. One case of ACC arising in a
fibroadenoma was reported [76].
Pre-operative findings can be difficult to differentiate from
invasive carcinoma NST. Both on fine-needle aspiration and
on core needle biopsy, attention must be paid to the
intracytoplasmic secretory granules.
On histology (Fig. 9), breast ACC can exhibits a variety of
architectural patterns, ranging from microcystic to solid.
Histological diagnosis is mainly based on cytologic features.
Neoplastic cells show abundant granular cytoplasm.
Intracytoplasmic granules can be seen on H&E, but when not
prominent, they are better appreciated on PAS with diastase.
ACC with microglandular architecture is characterized by
small glandular structures lined by atypical cells, with granu-
lar cytoplasm. No myoepithelial cells or basement membrane
are present. Areas of microglandular architecture can gradual-
ly merge with solid areas, composed of the same cell type.
In situ component can be present, showing features similar
to duct carcinoma in situ, with comedo-type necrosis, but
composed of cells with the typical granules.
Immunohistochemistry can help to reach the correct diag-
nosis. The typical immunohistochemical profile is the follow-
ing: amylase, lysozyme, and alpha-1-antichimotrypsin
positivity associatedwith strong and diffuse immunoreactivity
for S-100 and EMA.
No hormone receptor positivity or HER2 amplification
have been detected. On rare cases, androgen receptor positiv-
ity has been described [77].
The molecular profile of breast ACC is more similar to
conventional TNBC than that of salivary gland ACC. Breast
ACC is characterized by complex gene copy number alter-
ations, recurrent TP53 mutation and occasional PIK3CA
hotspot mutations [78].
ACC should be differentiated from several benign and ma-
lignant breast lesions showing a microglandular architecture
[26]. The diagnosis of ACC with microglandular pattern
should be limited to those cases composed of neoplastic
glands lined by atypical cells with intracytoplasmic serous
granules, devoid of myoepithelial cells and basement mem-
brane. The ACC glandular structures can be surrounded by
fine capillary vessels [26]. One must pay attention not to con-
fuse basement membrane of the capillaries with the basement
membrane of the neoplastic glands.
The most controversial differential diagnosis is between
ACC with microglandular architecture and microglandular
adenosis [26]. Some authors consider the two entities as part
of the same spectrum [78]. The presence of intracytoplasmic
granules, nuclear atypia and mitotic figures (even if rare)
should favour the diagnosis of ACC.
The relatively small number of cases reported in the litera-
ture together with the limited length of follow-up do not
allow drawing firm conclusions on the prognosis.
Despite these limitations, the cases reported to date
seem to have good prognosis [3].
Axillary lymph node metastases were reported in 10 out of
31 cases and local relapse in 4 of 38 cases.
Distant metastases have been described in 4 patients (bone,
liver, lung and meninges), 3 of whom died of disease
[3]. It is important to note that metastases also occurred
in cases that exhibited microglandular architecture on
histology [79, 80].
Tall cell carcinoma with reverse polarity (TCCRP)
TCCRP is an invasive carcinoma composed of elongated
cells, with eosinophilic and finely granular cytoplasm, ar-
ranged in solid and solid-papillary patterns. The neoplastic
cells show nuclear polarity toward the periphery of the neo-
plastic solid nests or papillae [2].
TCCRP was originally described in 2003 by Eusebi et al.
[81] who defined it as “Breast tumour resembling the tall cell
variant of papillary thyroid carcinoma”, due to its striking
similarity with the thyroid papillary carcinoma. Despite the
morphological similarities, no immunohistochemical markers
in common with thyroid carcinoma or RET/PTC alterations
were detected [82]. Papers published in the following years
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demonstrated that TCCRP is a unique entity of breast primary
[83].
Several papers appeared in the literature proposed different
names for this entity, thus creating an unclear terminology.
Therefore, the latest edition of WHO classification proposed
the unifying terminology of TCCRP [2].
TCCRP is a very rare breast tumour, affecting adult female
patients and presenting as a palpable breast nodule.
Nodules can affect all breast quadrants, usually being
1–2 cm in greatest dimension. Larger nodules have been
reported [83, 84]
Needle core biopsy shows the same features as observed in
surgical specimens; therefore, the same diagnostic criteria
should be applied.
On histology (Fig. 10), TCCRP is characterized by solid or
solid-papillary architecture. Margins are pushing and
multilobated. The neoplastic nests are composed of tightly
packed papillae, resulting in solid appearance. Areas with fol-
licular architecture can be encountered. Follicular structures
are filled with dense, eosinophilic secretion; foamy macro-
phages are focally present.
The most striking feature of TCCRP is the typical cytological
appearance of the neoplastic cells. Neoplastic cells are columnar
in shape, with eosinophilic and finely granular cytoplasm.
The nucleus is oval, with fine and clear chromatin, nuclear
grooves and pseudoinclusions, occupying about one third of
the cell. The neoplastic cells are oriented perpendicular to the
fibrovascular axis and have a basal pole, located on the oppo-
site side of the fibrovascular pole (“reverse polarity”). Fine
capillaries are arranged in a “garland-like fashion” around
the neoplastic nests.
Mitotic figures are very rare, as well as vascular and peri-
neural invasion. No necrosis is seen.
TCCRP shows expression of low and high-molecular weight
cytokeratins, and markers of mammary epithelium origin, such
as GATA3, mammaglobin, and GCDFP-15. In contrast,
markers of thyroid origin, such as TTF1 and thyroglob-
ulin are consistently negative in all cases [81, 83]. Most
TCPCRPs show strong positivity for anti-mitochondrial
antigen [83, 84]. Mitochondria are condensed at the
basal pole of the neoplastic cells, therefore highlighting
the “reverse polarity”.
Fig. 9 ACC; a ACC with
prominent microglandular
architecture is composed of small
glands infiltrating the breast
tissue. b the small glands are lined
by atypical cells; c the neoplastic
cells show a finely granular
cytoplasm; d most of the
neoplastic cells are EMApositive;
e the neoplastic cells are strongly
positive for Lysozyme
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In situ component has been described on rare occasions
[84]. In most cases, myoepithelial markers fail to reveal a
myoepithelial layer.
Hormone receptors and HER2 are usually negative. On
rare occasions, a minority of the neoplastic cells can stain
for oestrogen receptor [83]. Molecular studies detected
isocitrate dehydrogenase 2 (IDH2) [85–87] and phos-
phatidylinositol 3-kinase catalytic alpha (PIK3CA) hotspot
mutations [87].
Metastases from thyroid papillary carcinoma are easily ex-
cluded by the negativity of the thyroid markers. Negativity for
markers of endocrine differentiation excludes the diagnosis of
endocrine carcinoma.
Differential diagnosis can be more difficult with papillo-
mas of the breast, which can focally present features similar to
those of TCPCRP. Different from papillomas, TCCRP shows
the peculiar features throughout the entire nodule.
Myoepithelial cells are absent in TCCRP, while present in
papillomas. In addition, the strong and basally located immu-
noreactivity for the anti-mitochondrial antigen is typical of
TCPCRP and can help to reach the correct diagnosis.
TCPCRP is a low-grade carcinoma, with indolent clinical
course in most of the cases. Two cases with lymph node metasta-
ses have been reported [83, 84]; both patients were alive and well
after surgical removal of the tumour and the lymph node metasta-
sis. Only one case behaved in an aggressive fashion [88].
Secretory carcinoma
Secretory carcinoma represents an exceedingly rare breast neo-
plasm [89] with a predilection for children and young adults,
which explains the term “juvenile breast carcinoma” adopted by
Fig. 10 TCCRP; a TCCRP is
composed of neoplastic nests with
solid-papillary architecture; b at
higher power the neoplastic cells
are columnar, have granular and
eosinophilic cytoplasm. Nuclei
have fine chromatin and grooves;
c Anti-mitochondrial antigen is
strongly positive. Positivity is is
condensed at the basal pole of the
neoplastic cells; d Collagen IV
surrounds the neoplastic nests,
evidencing the basal membrane of
small capillaries; e CD31
evidences small capillaries
surrounding the neoplastic nests
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McDivitt and Stewart in 1966 [90]. Nevertheless, secretory carci-
noma can occur at any age and it is classified in the WHO blue
book based on its distinctive histopathological features [2].
Histologically (Fig. 11), this tumour typically shows a
microcystic growth pattern but tubular, solid, and even papil-
lary features can be encountered and patterns are often
admixed. Tumour cells are polygonal with eosinophilic granu-
lar or vacuolated cytoplasm. Nuclear pleomorphism is usually
mild to moderate.
At the molecular level, the presence of a balanced translo-
cation, t(12;15)(p13;q25), leading to the ETV6-NTRK3 fusion
gene is pathognomonic of secretory carcinomas, either of the
breast or of the salivary gland [91, 92]. Overexpression of the
chimeric NTRK3 protein has been reported to be typically
encountered in the nuclei of secretory carcinomas, as detected
by panTRK antibodies [92, 93].
Although most of secretory carcinoma patients present with
local disease and are surgically managed, this genetic alteration
may be of interest for those rare patients developing distant me-
tastases. TRK inhibitors have shown substantial and durable re-
sponses [94] and are FDA and EMA approved for metastatic
patients as well as for patients with unresectable local disease.
A cohort of secretory carcinoma with aggressive behaviour
has been recently reported, showing the presence of TERT
promotor mutations and loss of CDKN2A/B, in addition to
the typical ETV6-NTRK3 fusion [95].
The spectrum of differential diagnoses for this tumour may
encompass carcinomas with apocrine differentiation,
acinic cell carcinoma, and tall cell carcinoma with re-
versed polarity. In these instances, investigation of the
ETV6-NTR3 fusion is of diagnostic support.
Most cases of secretory carcinomas are of triple-negative
phenotype, however the clinical course of patients affected by
secretory carcinoma is typically indolent, with an excellent
prognosis even in patients with ipsilateral axillary lymph node
metastases [95–98]. Although remarkably rare (reviewed in
reference [96]) distant metastases can occur and advanced
stage patients have a dismal prognosis.
Conclusions
This review highlights the main histological, immunohisto-
chemical, and molecular features of TNBC of low malignant
potential. TNBC with low malignant potential are indeed rare
breast tumours, each with unique features. Knowledge on their
histological features and clinical behaviour are of utmost im-
portance for pathologists, to avoid overdiagnoses and overtreat-
ment. These lesions need to be appropriately discussed at the
multidisciplinary team meetings, to explain differences from
common forms of TNBCs.
Fig. 11 Secretory Carcinoma; a Secretory carcinoma shows a prominent
microcystic pattern of growth; b at higher power, the neoplastic cells show
vacuolated cytoplasm; c The chimeric NTRK3 protein is over-expressed; d
Fluorescent in situ hybridzation evidences the ETV6-NTRK3 fusion
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